At the news
? NEUTRALIMPACT 3/10 8-K filed Jun 26, 2026 at 16:15 ET
Atara Biotherapeutics disclosed the departure of Chief Accounting Officer Yanina Grant-Huerta (effective July 17, 2026) and the appointment of Kevin G. Sarney as interim CFO via a consulting agreement with Charles River CFO, Inc. The filing is a routine officer change and carries no material financial information.
- Chief Accounting Officer Yanina Grant-Huerta notified of employment end effective July 17, 2026.
- Kevin G. Sarney appointed interim CFO, principal financial officer, and principal accounting officer on June 26, 2026.
- Sarney, age 61, is a CPA with 25+ years of life science finance experience, serving via a consulting agreement with Charles River CFO, Inc. at an hourly rate.
- No compensation directly to Sarney; consulting agreement can be terminated with 30 days' notice.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access